Abstract

Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-associated mortality worldwide, accounting for more than 700000 deaths per year [1]. A large proportion of these patients are not candidates for potentially curative therapy, including liver transplantation or local ablation therapy, as they are diagnosed with advanced or metastatic disease. Sorafenib is an oral tyrosine kinase inhibitor used in cases of unresectable, advanced HCC that significantly improves progression-free and overall survival [2]. Achieving complete response with sorafenib is uncommon; however, if complete radiological response is obtained, the issue of the discontinuation of the treatment remains unsolved. There is also no standard of care for patients after orthotopic liver transplantation (OLTx) due to hepatocellular carcinoma and the choice of immunosuppression.